Beeler J F, Cooper R H
Department of Pharmacology, University of South Carolina School of Medicine, Columbia 29208.
Biochem J. 1995 Jan 1;305 ( Pt 1)(Pt 1):73-9. doi: 10.1042/bj3050073.
The effect of phorbol 12-myristate 13-acetate (PMA) on hepatocyte alpha 1-adrenergic receptors was determined by [3H]prazosin binding to plasma membranes from control and PMA-treated hepatocytes. Membranes from hepatocytes incubated with PMA (1 microgram/ml) for 1 h exhibited a 40% decrease in alpha 1-adrenergic receptors (481 +/- 10 fmol/mg of protein; mean +/- S.E.M. for three separate experiments) relative to vehicle-treated (dimethylformamide) hepatocytes (802 +/- 91 fmol/mg of protein; n = 3), with no significant effect on the KD. The PMA-induced decrease in alpha 1-adrenergic receptors was maximal by 30 min and half-maximal inhibition of [3H]prazosin binding occurred with a PMA concentration of approx. 15 ng/ml. Pretreatment of hepatocytes with staurosporine (5 microM) blocked the effect of PMA, and 4 beta-phorbol 13-monoacetate was ineffective, suggesting the involvement of protein kinase C (PKC). Treatment of hepatocytes with primaquine (300 microM) for 15 min decreased hepatocyte plasma membrane alpha 1-adrenergic receptors by 34.0 +/- 2.4% (mean +/- S.E.M. of three experiments). Removal of primaquine allowed essentially complete recovery (98 +/- 4%; mean +/- S.E.M. for five separate experiments) of plasma membrane [3H]prazosin binding within 20 min, suggesting that the alpha 1-adrenergic receptor undergoes endocytotic recycling. Addition of PMA (1 microgram/ml) to hepatocytes immediately after removal of primaquine, completely inhibited the increase in plasma membrane alpha 1-adrenergic receptors relative to control cells, but had no effect on hepatocytes whose cell surface alpha 1-receptors remaining after primaquine treatment had been inactivated by alkylation. These observations suggested that activation of PKC may facilitate the internalization of the alpha 1-adrenergic receptor in hepatocytes.
通过[³H]哌唑嗪与对照及佛波酯(PMA)处理的肝细胞质膜结合,测定了佛波酯12 - 肉豆蔻酸酯13 - 乙酸酯(PMA)对肝细胞α1 - 肾上腺素能受体的影响。与用溶剂(二甲基甲酰胺)处理的肝细胞相比,用PMA(1微克/毫升)孵育1小时的肝细胞质膜,其α1 - 肾上腺素能受体减少了40%(481±10飞摩尔/毫克蛋白质;三个独立实验的平均值±标准误),而溶剂处理的肝细胞为(802±91飞摩尔/毫克蛋白质;n = 3),对解离常数(KD)无显著影响。PMA诱导的α1 - 肾上腺素能受体减少在30分钟时达到最大,[³H]哌唑嗪结合的半数最大抑制浓度约为15纳克/毫升。用星形孢菌素(5微摩尔)预处理肝细胞可阻断PMA的作用,而4β - 佛波醇13 - 单乙酸酯无效,提示蛋白激酶C(PKC)参与其中。用伯氨喹(300微摩尔)处理肝细胞15分钟,肝细胞质膜α1 - 肾上腺素能受体减少34.0±2.4%(三个实验的平均值±标准误)。去除伯氨喹后,质膜[³H]哌唑嗪结合在20分钟内基本完全恢复(98±4%;五个独立实验的平均值±标准误),提示α1 - 肾上腺素能受体经历内吞再循环。去除伯氨喹后立即向肝细胞中添加PMA(1微克/毫升),相对于对照细胞,质膜α1 - 肾上腺素能受体的增加被完全抑制,但对经伯氨喹处理后细胞表面α1 - 受体已被烷基化失活的肝细胞无影响。这些观察结果提示PKC的激活可能促进肝细胞中α1 - 肾上腺素能受体的内化。